IBA Molecular Receives Positive Opinion For Marketing Dopacis(R) Across Europe

Gif-sur-Yvette, France, December 7, 2010 – IBA Molecular, member of IBA group and global developer of next generation radiopharmaceuticals used in molecular imaging, announced today that its registered radiopharmaceutical product Dopacis® (18F-Fluorodopa) received a positive opinion for the mutual recognition of the initial French authorization in 12 European Union concerned member states on November 10, 2010. This is the final step in the application process before marketing authorizations are granted by the national health authorities of the EU concerned member states.

Dopacis® is a radiopharmaceutical product that is currently approved for use in France in positron emission tomography (PET) for indications in neurology and oncology, specifically the differential diagnosis of extrapyramidal symptoms linked to Parkinson’s disease, and for diagnosis of neuroendocrine tumors. PET is a non-invasive method used in molecular imaging to visualize biological processes for the early detection and real-time monitoring of diseases.

Further to this positive opinion of the European Union’s Mutual Recognition Procedure (MRP), IBA Molecular expects to obtain marketing approvals in the EU concerned member states in 2011. Following this, the company will begin to supply Dopacis® to medical specialists from its European network of 24 PET sites, to make it available on a European scale. IBA Molecular’s sites in Bordeaux and Sarcelles (Paris) have already been validated in the European procedure and the company plans to extend approval to its additional European sites next.

“We are dedicated to providing solutions that address critical therapeutic areas through a more accurate and effective diagnosis and treatment of diseases, and a key element to this is proximity,” said François Labarre, vice president, Europe, IBA Molecular. “IBA Molecular’s 57 PET facilities worldwide represent the only global PET network in the industry today, and the largest one in Europe. Our goal is to provide specialists across Europe with innovative products such as Dopacis®, and the greatest access possible to them, as they must be delivered within a crucial window of time. This positive opinion brings us one step closer to doing so, and we will continue to advance other products in our pipeline – generic, proprietary and in-licensed – with this mission in mind.”

Developed by IBA Molecular in collaboration with research partners, Dopacis® is the company’s third PET radiopharmaceutical to be granted a marketing authorization in France following 18F-FDG, first obtained in 1998, and 18F-Na, obtained earlier this year. In parallel, as part of its commitment to providing educational, technical and marketing support to medical specialists, IBA Molecular has developed DopaSoft? associated software that simplifies diagnosis through quantified comparison possibilities and a rationalized diagnostic.

About IBA Molecular and IBA group

IBA Molecular is global developer, manufacturer and distributor of radiopharmaceutical products and supporting services used in molecular imaging. With radiopharmaceutical innovation capabilities that address indications in oncology, cardiology and neurology, in PET, SPECT and therapy, IBA Molecular has engineered a strong and unique product portfolio and pipeline of diagnostic tracers aimed at contributing to the development of the global trend towards personalized medicine and making molecular imaging a major discipline in healthcare. The company also provides educational, technical and marketing support to medical specialists worldwide to help better respond to unmet patient needs. IBA Molecular was awarded Frost & Sullivan’s European Radiopharmaceuticals Technology Leadership of the Year prize in 2010. Headquartered in Gif-sur-Yvette, France, IBA Molecular is a member of the Belgium-based IBA group. IBA develops and markets leading edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization. Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

Please visit www.iba-molecular.com and www.iba-worldwide.com for more information about IBA Molecular and IBA group.

Dopacis? and DopaSoft? are registered trademarks of IBA group.

Media contact: Christina Aplington Ballou PR for IBA Molecular +33 – 01 42 22 93 65 christina@balloupr.com

Meighan McFalls PR Assistant Ballou PR for IBA Molecular

Paris-London-New York

Direct: +33 (0)1 42 22 92 41 Office: +33 (0)1 42 22 24 10

www.balloupr.com 28, rue du Sentier - 75002 Paris